Sanofi
4Q Revenues: €8.7 billion (-2%)
4Q Earnings: €159 million (-80%)
FY Revenues:  €35.1 billion (+4%)
FY Earnings: €8.6 billion (+78%)
Comments: Pharmaceutical sales were up 3% in the quarter to €7.3 billion. Rare Disease sales increased 8% to €726 million. Genzyme sales were up 17% to $1.5 billion driven by contribution from new immunology franchise. Myozyme/ Lumizyme sales were $205 million in the quarter, up 12%. Cerezyme and Cerdelga sales were up 9% to €216 million supported by additional launches. Multiple Sclerosis sales grew 11% to €501 million, driven by Aubagio with sales up 14% to €389 million. Lemtrada sales were up 1% to €112 million. Oncology sales increased 4% in the quarter to €361 million. Diabetes sales decreased 16% to €1.5 billion, due to lower Sanofi glargine (Lantus and Toujeo) sales, reflecting exclusions from commercial formularies at CVS and UnitedHealthcare. Consumer Healthcare sales increased 52% to €1.2 billion reflecting the acquisition of Boehringer Ingelheim CHC business. Vaccines sales were up 9% to €1.4 billion and reflected the termination of the Sanofi Pasteur MSD joint venture in Europe. Sanofi Pasteur sales increased 1% impacted by order phasing effects and Dengvaxia. Results in the quarter reflect the acquisition Boehringer Ingelheim CHC business and the disposal of the Animal Health business.